Also known as: Vyjuvek, VYJUVEK
Vyjuvek (beremagene geperpavec-svdt) is an HSV-1 vector-based topical gene therapy used for wound treatment in dystrophic epidermolysis bullosa with COL7A1 mutations. It is applied weekly to selected wounds and was first approved in the U.S. in 2023, with subsequent label updates. It is a biologic gene therapy product from Krystal Biotech.
Amgen shares have fallen 12.6% in three months despite relatively solid Q1 results, while Novo Nordisk maintains a 54.6% global GLP-1 market share. Both companies face pipeline competition and pricing pressures.
Krystal Biotech said IOLITE enrollment for KB803 is complete and it remains on track for KB803 and KB801 registrational data readouts in 2026. The company also reported FDA platform technology designations for KB407 and KB111 and continued VYJUVEK expansion.
Krystal Biotech is set to report fourth-quarter results with analysts expecting $1.58 a share on $106.16 million in revenue. Investors are watching Vyjuvek growth and pipeline programs including KB801, KB407 and KB707.
Krystal Biotech posted Q4 2025 net revenue of $107.1 million from Vyjuvek sales, with full-year revenue reaching $389.1 million. The company expanded to over 90 patients across Germany, France, and Japan while advancing its pipeline with new FDA designations.
